Showing 391-400 of 9049 results for "".
GLP-1 Receptor Agonists: Current Roles in Medicine
https://practicaldermatology.com/issues/novemberdecember-2025/glp-1-receptor-agonists-current-roles-in-medicine/48897/In recent years, the popularity of glucagon-like peptide 1 receptor agonists (GLP-1RAs) has skyrocketed, along with interest in clinical applications beyond diabetes and weight management. Here, we present a brief review of GLP-1RAs, including a history, a look at the mechanism of action, pivotal reThe ESOP Model: An Alternative to PE for Dermatology Practices
https://practicaldermatology.com/issues/september-2025/the-esop-model-an-alternative-to-pe-for-dermatology-practices/37637/Not all practice models are as simple as private practice vs private equity. At Ada West Dermatology in Boise, Idaho, we’ve adopted a somewhat uncommon business model called an employee stock ownership plan (ESOP) and it’s worked very well for us.The Benefits of Private Practice: A Q&A with Joel Schlessinger, MD, FAAD
https://practicaldermatology.com/issues/september-2025/the-benefits-of-private-practice-a-qa-with-joel-schlessinger-md-faad/37630/While selling to and working for private equity–backed platforms may have its perks, many long-time private practitioners warn that the advantages of private practice are often not fully appreciated until it is too late. Practical Dermatology Chief Cosmetic Surgery Editor Emeritus Joel Schlessinger,Mergers and Acquisitions in Derm and Aesthetics: Market Outlook
https://practicaldermatology.com/issues/september-2025/mergers-and-acquisitions-in-derm-and-aesthetics-market-outlook/37631/We took a deeper look into the dermatology and aesthetics mergers and acquisitions (M&A) market in a conversation with two of our team members, Drew Thomas and Jordan Frickle, who are closely involved in this sector. The following discussion brings together their perspectives on current trends,Access Is Everything
https://practicaldermatology.com/topics/practice-management/access-is-everything/23942/The Safe Step Act of 2023 seeks to rein in fail-first policies and protect patients.How May Biosimilars Affect the Treatment of Psoriasis?
https://practicaldermatology.com/topics/psoriasis/how-may-biosimilars-affect-the-treatment-of-psoriasis/23867/The answer depends on several factors.Cognitive Bias And The Art of Doctoring
https://practicaldermatology.com/topics/practice-management/cognitive-bias-and-the-art-of-doctoring/23680/Rethinking the approach to diagnosis may reduce errors and improve patient interactions.Examining the Emotional Impact of Acne in a Virtual World
https://practicaldermatology.com/columns/clinical-focus-1/examining-the-emotional-impact-of-acne-in-a-virtual-world/23577/Acne patients are working hard to conceal their acne on Zoom.Checkpoint Blockade for Advanced cSCC: Exploring Newer Options
https://practicaldermatology.com/topics/skin-cancer-photoprotection/checkpoint-blockade-for-advanced-cscc-exploring-newer-options/23487/Two newer systemic options on the market provide hope in the fight against advanced cutaneous squamous cell carcinoma.Six Financial Actions to Take During the COVID-19 Crisis
https://practicaldermatology.com/topics/practice-management/six-financial-actions-to-take-during-the-covid-19-crisis/23293/Tips to help weather the storm and prepare for better days ahead.